File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Use of aspirin in Chinese after recovery from primary intracranial haemorrhage

TitleUse of aspirin in Chinese after recovery from primary intracranial haemorrhage
Authors
KeywordsAntiplatelet agents
Risk factors
Stroke/prevention
Issue Date2012
PublisherSchattauer GmbH. The Journal's web site is located at http://www.thrombosis-online.com
Citation
Thrombosis And Haemostasis, 2012, v. 107 n. 2, p. 241-247 How to Cite?
Abstract
Intracranial haemorrhage (ICH) accounts for ∼35% of all strokes in Chinese. Anti-platelet agent is often avoided after an index event due to the possibility of recurrent ICH. This single-centered observational study included 440 consecutive Chinese patients with a first spontaneous ICH surviving the first month performed during 1996-2010. The subjects were identified, and their clinical characteristics, anti-platelet therapy after ICH, and outcomes including recurrent ICH, ischaemic stroke, and acute coronary syndrome were checked from hospital records. Of these 440 patients, 56 patients (12.7%) were prescribed aspirin (312 patientaspirin years). After a follow-up of 62.2 ± 1.8 months, 47 patients had recurrent ICH (10.7%, 20.6 per 1,000 patient years). Patients prescribed aspirin did not have a higher risk of recurrent ICH compared with those not prescribed aspirin (22.7 per 1,000 patient-aspirin years vs. 22.4 per 1,000 patient years, p=0.70). Multivariate analysis identified age > 60 years (hazard ratio [HR]: 2.0, 95% confidence interval [CI]: 1.07-3.85, p=0.03) and hypertension (HR: 2.0, 95% CI: 1.06-3.75, p=0.03) as independent predictors for recurrent ICH. In a subgroup analysis including 127 patients with standard indications for aspirin of whom 56 were prescribed aspirin, the incidence of combined vascular events including recurrent ICH, ischaemic stroke, and acute coronary syndrome was statistically lower in patients prescribed aspirin than those not prescribed aspirin (52.4 per 1,000 patient-aspirin years, vs. 112.8 per 1,000 patient- years, p=0.04). In conclusion, we observed in a cohort of Chinese post-ICH patients that aspirin use was not associated with an increased risk for a recurrent ICH. © Schattauer 2012.
Persistent Identifierhttp://hdl.handle.net/10722/144558
ISSN
2013 Impact Factor: 5.760
2013 SCImago Journal Rankings: 2.437
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChong, BHen_HK
dc.contributor.authorChan, KHen_HK
dc.contributor.authorPong, Ven_HK
dc.contributor.authorLau, KKen_HK
dc.contributor.authorChan, YHen_HK
dc.contributor.authorZuo, MLen_HK
dc.contributor.authorLui, WMen_HK
dc.contributor.authorLeung, GKKen_HK
dc.contributor.authorLau, CPen_HK
dc.contributor.authorTse, HFen_HK
dc.contributor.authorPu, JKSen_HK
dc.contributor.authorSiu, CWen_HK
dc.date.accessioned2012-02-03T06:13:42Z-
dc.date.available2012-02-03T06:13:42Z-
dc.date.issued2012en_HK
dc.identifier.citationThrombosis And Haemostasis, 2012, v. 107 n. 2, p. 241-247en_HK
dc.identifier.issn0340-6245en_HK
dc.identifier.urihttp://hdl.handle.net/10722/144558-
dc.description.abstractIntracranial haemorrhage (ICH) accounts for ∼35% of all strokes in Chinese. Anti-platelet agent is often avoided after an index event due to the possibility of recurrent ICH. This single-centered observational study included 440 consecutive Chinese patients with a first spontaneous ICH surviving the first month performed during 1996-2010. The subjects were identified, and their clinical characteristics, anti-platelet therapy after ICH, and outcomes including recurrent ICH, ischaemic stroke, and acute coronary syndrome were checked from hospital records. Of these 440 patients, 56 patients (12.7%) were prescribed aspirin (312 patientaspirin years). After a follow-up of 62.2 ± 1.8 months, 47 patients had recurrent ICH (10.7%, 20.6 per 1,000 patient years). Patients prescribed aspirin did not have a higher risk of recurrent ICH compared with those not prescribed aspirin (22.7 per 1,000 patient-aspirin years vs. 22.4 per 1,000 patient years, p=0.70). Multivariate analysis identified age > 60 years (hazard ratio [HR]: 2.0, 95% confidence interval [CI]: 1.07-3.85, p=0.03) and hypertension (HR: 2.0, 95% CI: 1.06-3.75, p=0.03) as independent predictors for recurrent ICH. In a subgroup analysis including 127 patients with standard indications for aspirin of whom 56 were prescribed aspirin, the incidence of combined vascular events including recurrent ICH, ischaemic stroke, and acute coronary syndrome was statistically lower in patients prescribed aspirin than those not prescribed aspirin (52.4 per 1,000 patient-aspirin years, vs. 112.8 per 1,000 patient- years, p=0.04). In conclusion, we observed in a cohort of Chinese post-ICH patients that aspirin use was not associated with an increased risk for a recurrent ICH. © Schattauer 2012.en_HK
dc.languageengen_US
dc.publisherSchattauer GmbH. The Journal's web site is located at http://www.thrombosis-online.comen_HK
dc.relation.ispartofThrombosis and Haemostasisen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectAntiplatelet agentsen_HK
dc.subjectRisk factorsen_HK
dc.subjectStroke/preventionen_HK
dc.subject.meshAge Factorsen_HK
dc.subject.meshAspirin - administration & dosage - adverse effectsen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshFollow-Up Studiesen_HK
dc.subject.meshHumansen_HK
dc.subject.meshIntracranial Hemorrhages - drug therapy - physiopathology - surgeryen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPlatelet Aggregation Inhibitors - administration & dosage - adverse effectsen_HK
dc.subject.meshRecurrenceen_HK
dc.subject.meshRegistriesen_HK
dc.subject.meshRisk Factorsen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleUse of aspirin in Chinese after recovery from primary intracranial haemorrhageen_HK
dc.typeArticleen_HK
dc.identifier.emailLau, KK: gkklau@hku.hken_HK
dc.identifier.emailChan, YH: chanwill@hku.hken_HK
dc.identifier.emailLeung, GKK: gilberto@hkucc.hku.hken_HK
dc.identifier.emailTse, HF: hftse@hkucc.hku.hken_HK
dc.identifier.emailSiu, CW: cwdsiu@hkucc.hku.hken_HK
dc.identifier.authorityLau, KK=rp01499en_HK
dc.identifier.authorityChan, YH=rp01313en_HK
dc.identifier.authorityLeung, GKK=rp00522en_HK
dc.identifier.authorityTse, HF=rp00428en_HK
dc.identifier.authoritySiu, CW=rp00534en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1160/TH11-06-0439en_HK
dc.identifier.pmid22187066en_HK
dc.identifier.scopuseid_2-s2.0-84856638385en_HK
dc.identifier.hkuros198412en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84856638385&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume107en_HK
dc.identifier.issue2en_HK
dc.identifier.spage241en_HK
dc.identifier.epage247en_HK
dc.identifier.isiWOS:000300748800005-
dc.publisher.placeGermanyen_HK
dc.identifier.scopusauthoridChong, BH=53263288800en_HK
dc.identifier.scopusauthoridChan, KH=36493922700en_HK
dc.identifier.scopusauthoridPong, V=26025247300en_HK
dc.identifier.scopusauthoridLau, KK=22635159600en_HK
dc.identifier.scopusauthoridChan, YH=22633700600en_HK
dc.identifier.scopusauthoridZuo, ML=54958367700en_HK
dc.identifier.scopusauthoridLui, WM=7101851125en_HK
dc.identifier.scopusauthoridLeung, GKK=35965118200en_HK
dc.identifier.scopusauthoridLau, CP=7401968501en_HK
dc.identifier.scopusauthoridTse, HF=7006070805en_HK
dc.identifier.scopusauthoridPu, JKS=35094475800en_HK
dc.identifier.scopusauthoridSiu, CW=7006550690en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats